Posted on 28/02/201814/03/2018 Singapore eDevelopment Limited (Stock Code 40V)’s biomedical subsidiary confirms the LB2 drug efficacy against Ebola
Posted on 10/01/201806/03/2018 Singapore eDevelopment Limited (Stock Code: 40V)’s Biomedical Subsidiary Completes Initial Cancer Research for New Universal Therapeutic Drug Platform
Posted on 09/01/201806/03/2018 Global BioLife, a Biomedical Subsidiary of Singapore eDevelopment Limited, Completes Cancer Research for New Universal Therapeutic Drug Platform
Posted on 08/01/201814/03/2018 Singapore eDevelopment Names Former USAssistant Surgeon General, Dr Roscoe Moore, as Senior Scientific Adviser to its Biomedical Arm
Posted on 01/11/201706/03/2018 Singapore eDevelopment’s Biomedical Subsidiary Confirms 100% Repellency of 3F Mosquito Fragrance
Posted on 24/10/201706/03/2018 Singapore Exchange-Listed Singapore eDevelopment’s U.S. Subsidiary Global BioLife Develops Breakthrough Modified Sugar
Posted on 15/08/201706/03/2018 Singapore eDevelopment Limited’s Biomedical Subsidiary forms Working Collaboration to Develop Functional Fragrances to Fight Mosquito-Borne Diseases
Posted on 22/05/201706/03/2018 Singapore eDevelopment Limited’s Bio-Medical Subsidiary Initiates Advanced Research of a New Universal Therapeutic Drug Platform, Led By Two-Time Nobel Prize Nominee
